<p class="ql-align-justify">Best Healthcare Investment Opportunities:</p><p class="ql-align-justify"><br></p><p class="ql-align-justify">Global <a href="https://globalcancertechnology.com/"><strong>Cancer Technology</strong></a> is offering accredited investors pre-IPO shares. Please contact us for additional investment information.</p>

Different Types of Breast Cancer

<h2>When There’s a Will – There’s a Way</h2><h2>Our team is committed to improving the lives of cancer patients.</h2><h1>Global Cancer Technology
</h1><h4>Because cancer shouldn’t be a death sentence
</h4><p><span>Global Cancer Technology is a non-revenue biopharma company developing a novel treatment for cancers. We are developing a small molecule PI3K inhibitor that can cross the blood-brain barrier and has shown promise in preclinical cell and animal studies.</span></p><p><span dir="ltr">To date, we have research efforts underway studying how our PI3K inhibitor, GCT- 007 slows the growth of <a href="https://globalcancertechnology.com/glioblastoma/" dir="ltr">glioblastoma</a> (brain cancer) cells. Glioblastoma is the most malignant and aggressive form of brain cancer. It is particularly adept at escaping an immune defense response and has shown strong resistance against PI3K/AKT/mTOR inhibitors, hence the importance of finding novel ways to treat this deadly disease.</span></p><p><span dir="ltr">Our PI3K inhibitor also exhibits similar growth inhibition in triple-negative <a href="https://globalcancertechnology.com/invest-now/" rel="noopener" dir="ltr">breast cancer</a> tumors.</span></p><img width="42" height="515" src="https://globalcancertechnology.com/wp-content/uploads/2022/02/green-strip.jpg" alt=""><h2>Problem</h2><p>Each year, about one-third of those diagnosed with cancer (605,500) will die.</p><p dir="ltr"><strong dir="ltr"><a href="https://globalcancertechnology.com/glioblastoma/" rel="noopener" dir="ltr">Glioblastoma</a></strong>, a rare and deadly form of brain cancer, is diagnosed in about 5 of every 100,000 people worldwide. Incidence is increasing according to studies published by the&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302718/" dir="ltr">NCBI</a>. <a href="https://globalcancertechnology.com/breast-cancer/" rel="noopener" dir="ltr"><strong dir="ltr">Breast cancer</strong></a> is diagnosed in ~265,000 people each year: 10-15% have triple negative cancer which often spreads to the lymph nodes and kills around one-third of patients.</p><p>We believe we have a solution for these deadly cancers.</p><h2>Solution</h2><p>Our compound, GCT- 007&nbsp; is a member of a unique, mechanistically distinct class of selective inhibitors that target PI3K. GCT- 007 can:</p><UL><LI>potently and specifically inhibit PI3K</LI><LI>cross the blood-brain barrier (few compounds can do this)</LI><LI>modulate immune cell function and inflammatory response.</LI></UL><p>In preclinical studies, our compound has been shown to induce arrested growth in cell cultures, to increase immune recognition, and to increase sensitivity to radiation. Combined, these effects make the glioblastoma tumor weaker and more susceptible to treatment.</p><h2>Business Model</h2><p>The pathway to commercialization of any drug is straightforward and well developed. It begins with an idea and ends with an FDA approval</p><h2>Timeline</h2><p>Research takes time and money. Bringing a drug to market now costs an average of $ 1.3 Billion and can take up to a decade in time. It is extremely challenging and with less funding, it can take even longer. Yet the potential to change lives makes it an attractive pursuit despite the complexity and risks.</p><img width="785" height="296" src="https://globalcancertechnology.com/wp-content/uploads/2022/11/TIMELINE-1.jpg" alt="TIMELINE" srcset="https://globalcancertechnology.com/wp-content/uploads/2022/11/TIMELINE-1.jpg 1683w, https://globalcancertechnology.com/wp-content/uploads/2022/11/TIMELINE-1-300x113.jpg 300w, https://globalcancertechnology.com/wp-content/uploads/2022/11/TIMELINE-1-1024x386.jpg 1024w, https://globalcancertechnology.com/wp-content/uploads/2022/11/TIMELINE-1-768x290.jpg 768w, https://globalcancertechnology.com/wp-content/uploads/2022/11/TIMELINE-1-1536x580.jpg 1536w"><h2>Patent/Licenses/IP</h2><h5>GCT has acquired the right/license to the following the patents</h5><img width="143" height="33" src="https://globalcancertechnology.com/wp-content/uploads/2022/02/cl-1.jpg" alt="cl-1"><UL><LI><span>WO,2019,199874-Wo,2019,199864 for the glioblastoma drug</span></LI></UL><img width="143" height="33" src="https://globalcancertechnology.com/wp-content/uploads/2022/02/cl-3.jpg" alt="cl-3"><UL><LI><span>Intellectual Property for whole blood Glioblastoma biomarkers</span></LI></UL><UL><LI><span>Global Cancer Technology has recently filed a patent for using our GBM drug with   checkpoint inhibitors</span></LI></UL><img src="http://globalcancertechnology.com/wp-content/uploads/2022/01/logo.png" alt="" width="208" height="38"><h3><span>Get In Touch With Us</span></h3><p dir="ltr">16776 Bernardo Center Drive #203<br dir="ltr">
San Diego, CA 92128</p>

Global Cancer Technology is working on a novel treatment for cancers, glioblastoma treatment technology and cancer inhibitors, know more about our cancer treatment technology.

food

Food

When There’s a Will – There’s a Way

Our team is committed to improving the lives of cancer patients.

Because cancer shouldn’t be a death sentence

<p><span>Global Cancer Technology is a non-revenue biopharma company developing a novel treatment for cancers. We are developing a small molecule PI3K inhibitor that can cross the blood-brain barrier and has shown promise in preclinical cell and animal studies. </span> </p>

<p><span>To date, we have research efforts underway studying how our PI3K inhibitor, GCT- 007 slows the growth of <a href="https://globalcancertechnology.com/glioblastoma/">glioblastoma </a>(brain cancer) cells. Glioblastoma is the most malignant and aggressive form of brain cancer. It is particularly adept at escaping an immune defense response and has shown strong resistance against PI3K/AKT/mTOR inhibitors, hence the importance of finding novel ways to treat this deadly disease. </span> </p>

<p><span>Our PI3K inhibitor also exhibits similar growth inhibition in triple-negative <a href="https://globalcancertechnology.com/invest-now/">breast cancer </a>tumors. </span> </p>

<p>Each year, about one-third of those diagnosed with cancer (605,500) will die. </p>

<p><strong><a href="https://globalcancertechnology.com/glioblastoma/">Glioblastoma </a> </strong>, a rare and deadly form of brain cancer, is diagnosed in about 5 of every 100,000 people worldwide. Incidence is increasing according to studies published by the <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302718/">NCBI </a>. <a href="https://globalcancertechnology.com/breast-cancer/"><strong>Breast cancer </strong> </a>is diagnosed in ~265,000 people each year: 10-15% have triple negative cancer which often spreads to the lymph nodes and kills around one-third of patients. </p>

<p>We believe we have a solution for these deadly cancers. </p>

<p>Our compound, GCT- 007  is a member of a unique, mechanistically distinct class of selective inhibitors that target PI3K. GCT- 007 can: </p>

<ul><li>potently and specifically inhibit PI3K </li><li>cross the blood-brain barrier (few compounds can do this) </li><li>modulate immune cell function and inflammatory response. </li> </ul>

<p>In preclinical studies, our compound has been shown to induce arrested growth in cell cultures, to increase immune recognition, and to increase sensitivity to radiation. Combined, these effects make the glioblastoma tumor weaker and more susceptible to treatment. </p>

<p>The pathway to commercialization of any drug is straightforward and well developed. It begins with an idea and ends with an FDA approval </p>

<p>Research takes time and money. Bringing a drug to market now costs an average of $ 1.3 Billion and can take up to a decade in time. It is extremely challenging and with less funding, it can take even longer. Yet the potential to change lives makes it an attractive pursuit despite the complexity and risks. </p>

GCT has acquired the right/license to the following the patents

<ul><li><span>WO,2019,199874-Wo,2019,199864 for the glioblastoma drug </span> </li> </ul>

<ul><li><span>Intellectual Property for whole blood Glioblastoma biomarkers </span> </li> </ul>

<ul><li><span>Global Cancer Technology has recently filed a patent for using our GBM drug with checkpoint inhibitors </span> </li> </ul>

<p>16776 Bernardo Center Drive #203<br>San Diego, CA 92128 </p>

Cancer Technology | Cancer Inhibitors Technology

Different Types of Breast Cancer

fidicon devices's ideas are part of this journey:

Related collections

Similar ideas